PBYI Share Price

Open 129.10 Change Price %
High 131.00 1 Day -0.80 -0.62
Low 127.25 1 Week 0.00 0.00
Close 127.30 1 Month 2.95 2.37
Volume 436859 1 Year 76.90 152.58
52 Week High 131.00
52 Week Low 0.00
PBYI Important Levels
Resistance 2 130.78
Resistance 1 129.34
Pivot 128.52
Support 1 125.26
Support 2 123.82
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
RAI 65.40 -2.23%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
TREX 109.45 25.65%
HZO 18.55 22.04%
SSD 55.74 14.62%
TBI 27.10 14.11%
SSTK 38.99 13.84%
KAI 113.60 13.09%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Puma Biotechnology Inc (NYSE: PBYI)

PBYI Technical Analysis 5
As on 31st Oct 2017 PBYI Share Price closed @ 127.30 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 65.46 & Strong Buy for SHORT-TERM with Stoploss of 107.55 we also expect STOCK to react on Following IMPORTANT LEVELS.
PBYI Target for November
1st Target up-side 135.83
2nd Target up-side 141.81
3rd Target up-side 147.79
1st Target down-side 118.77
2nd Target down-side 112.79
3rd Target down-side 106.81
PBYI Other Details
Segment EQ
Market Capital 620310592.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.pumabiotechnology.com
PBYI Address
PBYI
10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
Phone: 424-248-6500
Fax: 424-248-6501
PBYI Latest News
Interactive Technical Analysis Chart Puma Biotechnology Inc ( PBYI NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Puma Biotechnology Inc
PBYI Business Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products to enhance cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.